June 17th, 2009 Message from former President

June 17, 2009Message from former President Richard T. Silver, MD

Dear Colleagues:
I wish to tell you of a very interesting opportunity for your patients that we are conducting at Cornell. Wyeth is sponsoring a drug trial comparing imatinib to their new drug bosutinib in untreated patients with chronic myeloid leukemia. Both drugs will be provided free. This may be of some importance for those patients who have a 10% or 20% deduction or a donor. Bosutinib has been thought to be equally or more effective than imatinib with less toxicity. It has already been used in imatinib-resistant patients with success. If you have such patients, please call 212-746-2098 for anyone in our group in the Leukemia/Myeloproliferative Disease section who are all well-qualified to see such patients.I send my best regards.

Sincerely,
Richard T. Silver, M.D.
Attending PhysicianProfessor of MedicineDirector, Leukemia and Myeloproliferative Center